A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
Eligible age
18–74 yrs
Accepts
All genders
Locations
18 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
X-NOVA2 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of azetukalner as a monotherapy in adult participants diagnosed with Major Depressive Disorder (MDD)
Sponsor: Xenon Pharmaceuticals Inc.
Where it's recruiting
Phoenix
Little Rock · Rogers
Glendale · Huntington Beach · Irvine · Los Angeles …
Cromwell
Coral Springs · Hialeah · Jacksonville · Lakeland …
Atlanta · Decatur · Marietta · Savannah
Boise
Chicago
Boston · Springfield
Las Vegas
Albuquerque
Brooklyn · Staten Island
Source: ClinicalTrials.gov · NCT06775379 · last updated 2025-10-22